Drotrecogin alfa (activated)

Drugs

Volumn 62, Issue 4, 2002, Pages 617-630

  Lyseng Williamson, Katherine A ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; DROTRECOGIN; INTERLEUKIN 6;

BRAIN EDEMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS;

EID: 0036202034     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262040-00006     Document Type: Review

References (61)

1. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
2. Current concepts: Treating patients with severe sepsis
3. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care
4. First economic analysis paints shocking picture of severe sepsis in Europe
5. Innovative therapies for sepsis
6. Time course of hemostatic abnormalities in sepsis and its relation to outcome
7. Towards a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation
8. Alterations in coagulation and fibrinolysis during sepsis
9. The role of endothelium in changes in procoagulant activity in sepsis
10. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
11. Inflammation and thrombosis: Mutual regulation by protein C
12. Pathogenesis of disseminated intravascular coagulation in sepsis
13. Role of pro- and anti-inflammatory cytokines during inflammation: Experimental and clinical findings
14. 2.8 Å crystal structure of G1a-domainless activated protein C
15. Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis
16. Protein C, protein S and C4b-binding protein in severe infection and septic shock
17. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complication
18. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies
19. Activated protein C versus protein C in severe sepsis
20. Efficacy and safety of recombinant human activated protein C for severe sepsis
21. Age-related differences in outcome and severity of DIC in children with septic shock and purpura
22. Current disease management strategies in the treatment of serious infections
23. Adjunctive drug treatment in severe hypoxic respiratory failure
24. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis
25. Recent advances in the management of pleural sepsis: What is the evidence?
26. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis
27. Antibiotics, cytokines, and endotoxin: A complex and evolving relationship in Gram-negative sepsis
28. The significance of endotoxin release in experimental and clinical sepsis in surgical patients - Evidence for antibiotic-induced endotoxin release?
29. Bedside prediction of mortality for bacteremic sepsis: A dynamic analysis of ICU patients
30. Strategies to rationalize sepsis management - A review of 4 years' experience in Dundee
31. Antiendotoxin strategies for the prevention and treatment of septic shock: New approaches and future directions
32. Recent advances in therapy of sepsis: Focus on recombinant bactericidal/permeability-increasing protein (BPI)
33. Treatment of sepsis: Past and future avenues
34. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
35. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-γ, or phorbol ester
36. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis
37. The endothelial cell protein C receptor aid in host defense against Escherichia coli sepsis
38. Endothelial cell protein C receptor plays an important role in protein C activation in vivo
39. Dysfunction of endothelial protein C activation in severe meningococcal sepsis
40. Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: In vivo and in vitro studies
41. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
42. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats
43. Potentiation of urokinase induced fibrinolysis by human activated protein C
44. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates
45. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis
46. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis
47. Local delivery of activated protein C via drug-eluting stent inhibits platelet thrombus in vivo
48. Effect of activated protein C on endotoxin shock in rabbits
49. Comparison of hemorrhagic effect of heparin and human activated protein C with use of thrombostat 4000
50. Interaction of recombinant human activated protein C with antiplatelet agents in a guinea pig thrombosis model
51. The haematological manifestations of sepsis
52. Recombinant human activated protein C for severe sepsis
53. Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma
54. 2-macroglobulin, in patients with disseminated intravascular coagulation
55. Inhibition and complexation of activated protein C by two major inhibitors in plasma
56. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
57. Using high quality clinical databases to complement the results of randomised controlled trials: The case of recombinant human activated protein C
58. The effect of recombinant human activated protein C (rhAPC) on organ dysfunction and functional recovery in severe sepsis
59. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C